Dr. A. Lindsay Frazier’s clinical focus within pediatric oncology is germ cell tumors (GCT). Her involvement in germ cell tumors ranges from clinical trials, to biology and to epidemiology. She has served on the steering committee of the Childrens’ Oncology Group’s (COG) germ cell committee since 1996 and assumed leadership of the committee in 2007 which entails oversight of all current protocols and development of the strategic initiatives for future protocols across the spectrum of disease from low risk to high risk to salvage therapies.. She has served as the Chair of the COG protocol for low/intermediate risk germ cell tumors protocol (AGCT0132), Vice-Chair of the COG protocol for relapsed germ cell tumors and for high risk germ cell tumors. She has authored numerous papers and chapters on pediatric germ cell tumors and has recently edited a book for Springer of Pediatric Germ Cell Tumors. Dr. Frazier led the formation of an international group of germ cell tumor specialists from the United States and United Kingdom, “MaGIC—the Malignant Germ Cell International Collaboration”  that has merged their clinical trial data from the past 25 years to create a more comprehensive risk classification system. This risk classification system has lead to the development of a new set of RCT currently under review at COG. To have sufficient sample size to conduct these trials, Dr. Frazier has set up an international collaboration that include investigators from Brazil, TATA Memorial Hospital in Mumbai and 57357 Childrens Cancer Center in Cairo. MaGIC has also recently expanded to include the clinical trial data of the adult GCT trials from Gynecologic Oncology Group (ovarian GCT), the Medical Research Council (testicular cancer) so that this risk classification can be applied to adolescents and young adult. Dr. Frazier is leading the development of an international poor risk germ cell tumor protocol that will include adult men and women with GCT as well as pediatric patients, that will be a cooperative trial including England, the US, Australia-New Zealand and Germany.

Dr. Frazier’s other main focus is on the development of adolescent and young adult oncology, at a national level and also at the Dana Farber Cancer Institute. Dr. Frazier was appointed to the steering committee of the NCCN AYA Guidelines in 2013. She currently serves on the board of medical advisors for Teen Cancer America. In 2014, Dr. Frazier is leading an AYA task force at DFCI of medical and pediatric physicians and psychologists to explore opportunities to improve care for our patients between the ages of 15-25.

Dr. Frazier also holds an appointment in epidemiology at the Harvard School of Public Health Dr. Frazier leads the Childhood Oncology Registries project –iCOLOR-for the Global Health Initiative of the Dana-Farber Children’s Cancer and Blood Disorders Center. In 2014, population-based cancer registries have been initiated in Guatemala and El Salvador. These foundational projects will serve as the basis for cancer epidemiology in Central America. The expectation is that these projects will expand to the other two low-middle income countries in Central America, Nicaragua and Honduras, in 2015. Dr. Frazier has been asked to serve on the advisory board of the Massachusetts State Cancer Registry. She will be co-leading an international workshop on pediatric cancer registration, funded by NCI, at SIOP in Toronto in 2014.

Dr. Frazier was a founding member and served as the co-director of the Growing Up Today Study, a national cohort study of 27,000 offspring of the women in the Nurses’ Health Study. Her epidemiologic expertise is the study of adolescent factors that predispose to adult malignancies, such as factors which predispose to the development of benign breast disease, predictors of obesity, tobacco use and sun protection. Dr. Frazier’s interest in adolescent cancer prevention is reflected in her co-leadership of the DF/HCC Cancer Risk and Disparities Program and her appointment to the Adolescent Cancer Prevention Advisory Committee at the Centers for Disease Control.